PCI in Beijing Friendship Hospital

Cardiovascular Diseases Clinical Trial

— BF-PCI  

Official title:

Risk Factor for Percutaneous Coronary Intervention in the Beijing Friendship Hospital

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05728580
• Other study ID #: BF-PCI
• Status: Recruiting
• Start date: December 31, 2017
• Est. completion date: December 31, 2027

Study information

• Verified date: December 2023
• Source: Beijing Friendship Hospital
• Contact: Bingbing Ke, Dr
• Phone: 15510286857
• Email: 1017120710[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this study is to discover the potential risk factors related percutaneous coronary intervention. It aims to stratify the risk of PCI patients and discover the prognostic value of these risk fators.

Description:

Coronary heart disease is the main cause of death worldwide. Ischemic heart disease is the most common cause of death. Percutaneous coronary intervention (PCI) is a very effective treatment for coronary heart disease, which can alleviate myocardial ischemia and reduce the mortality of patients with acute myocardial infarction. It is an important measure to treat coronary heart disease at present. However, the study found that the incidence of major adverse cardiac and cerebrovascular event (MACCE) after PCI was more than 10%, which could reach 20-30% in elderly patients. Therefore, the purpose of this study is to investigate the risk factors related to PCI and to intervene or change the treatment strategy as early as possible. Risk stratification was performed in these patients for improving the quality of life of patients, reducing medical costs, and improving the life expectancy of patients. Patients with PCI in Beijing friendship hospital are enrolled.The primary outcome is MACCE and all-cause mortality.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 18 years at the time of admission to the hospital

• PCI patients with coronary heart disease: according to the criteria interpreted in the 2011 American Guidelines for Percutaneous Coronary Intervention. The successful diagnostic criteria of PCI: residual stenosis of the treated vessel<10% (preferably 0%), and the forward flow is TIMI grade 3, there is no dissection that affects the flow, no important side branch occlusion, no visible thrombus and peripheral embolism.

Exclusion Criteria:

• Patients who failed in PCI treatment;

• Current known inability to follow instructions or comply with follow-up procedures.

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Percutaneous Coronary Intervention

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MACCE	defined as a composite of all cause mortality, any myocardial infarction (MI), any revascularization, stroke, and heart failure hospitalization	These data is collected during follow-up for 5 years after discharge
Primary	All-cause mortality	whether recidivation happened,whether other related disease happened	These data is collected during follow-up for 5 years after discharge